Skip to main content

Table 3 Clinical and molecular characteristics of study cohort

From: Comprehensive analysis of mutations and clonal evolution patterns in a cohort of patients with cytogenetically normal acute myeloid leukemia

Patient

Status

Age at Dx (years)

Blast%

G-banding Karyotype

Molecular diagnostic (28 translocations)

AML prognostic marker

1

P

26

55

46,XX [20]

Negative

NPM1 (MutA) positive,

FLT3-ITD positive

R

 

30

46,XX [20]

Negative

NPM1 (MutA) positive,

FLT3-ITD negative

2

P

17

> 80

46,XX [20]

Negative

NPM1 negative, FLT3-ITD negative

R

 

60

46,XX [20]

Negative

NPM1 negative, FLT3-ITD negative

3

P

43

91

46,XY [20]

Negative

NPM1 negative, FLT3-ITD negative

R

 

94

46,XY [20]

Negative

NPM1 negative, FLT3-ITD negative

4

P

40

11

46,XY [20]

Negative

NPM1 negative, FLT3-ITD negative

R

 

70

46,XY [20]

Negative

NPM1 negative, FLT3-ITD negative

5

P

51

54

46,XY [20]

Negative

NPM1 (MutA) positive,

FLT3-ITD negative

R

 

20

46,XY [20]

Negative

NPM1 (MutA) positive,

FLT3-ITD negative

6

P

33

61

46,XX [20]

Negative

NPM1 negative, FLT3-ITD negative

R

 

91

46,XX [20]

Negative

NPM1 negative, FLT3-ITD negative